Entrada Therapeutics Inc
NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-03
Entrada Therapeutics Inc (TRDA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $0.00 | $-4.65M | — | — | — |
| 2020 | $0.00 | $-26.52M | — | — | — |
| 2021 | $0.00 | $-50.07M | — | — | — |
| 2022 | $25.26M | $-87.46M | -7.50% | -384.99% | -346.23% |
| 2023 | $129.01M | $-6.68M | 100.00% | -2.45% | -5.18% |
| 2024 | $210.78M | $65.63M | 100.00% | 22.30% | 31.13% |
| 2025 | $25.42M | $-143.75M | 83.89% | -613.66% | -565.48% |
Frequently asked questions
What is Entrada Therapeutics Inc's revenue?
Entrada Therapeutics Inc's trailing twelve-month revenue is $5.74M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is TRDA?
In its most recent fiscal year, TRDA ran a gross margin of 83.89%, an operating margin of -613.66%, and a net margin of -565.48%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does TRDA generate?
TRDA produced $-129.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is TRDA's balance sheet healthy?
TRDA holds $90.39M in cash and equivalents against — in long-term debt, on $306.13M of shareholder equity. That debt is best read against the cash flow the business throws off each year.